IMMPHENTIV Drug Patent Profile
Which patents cover Immphentiv, and when can generic versions of Immphentiv launch?
Immphentiv is a drug marketed by Hikma and is included in one NDA. There are three patents protecting this drug.
The generic ingredient in IMMPHENTIV is phenylephrine hydrochloride. There is one drug master file entry for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the phenylephrine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Immphentiv
A generic version of IMMPHENTIV was approved as phenylephrine hydrochloride by HIKMA on December 20th, 2012.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for IMMPHENTIV?
- What are the global sales for IMMPHENTIV?
- What is Average Wholesale Price for IMMPHENTIV?
Summary for IMMPHENTIV
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 4 |
| Patent Applications: | 2,288 |
| Drug Prices: | Drug price information for IMMPHENTIV |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for IMMPHENTIV |
| DailyMed Link: | IMMPHENTIV at DailyMed |
Pharmacology for IMMPHENTIV
| Drug Class | alpha-1 Adrenergic Agonist |
| Mechanism of Action | Adrenergic alpha1-Agonists |
US Patents and Regulatory Information for IMMPHENTIV
IMMPHENTIV is protected by three US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hikma | IMMPHENTIV | phenylephrine hydrochloride | SOLUTION;INTRAVENOUS | 203826-004 | Mar 9, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Hikma | IMMPHENTIV | phenylephrine hydrochloride | SOLUTION;INTRAVENOUS | 203826-005 | Mar 9, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Hikma | IMMPHENTIV | phenylephrine hydrochloride | SOLUTION;INTRAVENOUS | 203826-004 | Mar 9, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
